SCATTOLIN, DANIELA

SCATTOLIN, DANIELA  

Mostra records
Risultati 1 - 5 di 5 (tempo di esecuzione: 0.007 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 2020 Dal Maso, A.Ferro, A.Lorenzi, M.Scattolin, D.Frega, S.Bonanno, L.Indraccolo, S.Calabrese, F.Guarneri, V.Conte, P. F.Pasello, G. + ANNALS OF ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Bonanno, L.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 2019 Pasello, GiuliaDal Maso, AlessandroLorenzi, MartinaScattolin, DanielaUrso, LoredanaZulato, ElisabettaFrega, StefanoBonanno, LauraIndraccolo, StefanoCalabrese, FiorellaConte, Pierfranco + JOURNAL OF CLINICAL ONCOLOGY - -
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 2021 Lorenzi, MartinaFerro, AlessandraScattolin, DanielaDal Maso, AlessandroIndraccolo, StefanoCalabrese, FiorellaBonanno, LauraConte, PierFrancoGuarneri, ValentinaPasello, Giulia + THE ONCOLOGIST - -
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 2021 Dal Maso, ALorenzi, MFerro, AScattolin, DIndraccolo, SFrega, SMenis, JBonanno, LCalabrese, FGuarneri, VConte, PPasello, G + FUTURE ONCOLOGY - -